arrow
P

Patrick Schloemer

Bayer AG
H指数:13
被引数:3,663

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE

在FINE-ONE研究的预设分析中考察非奈利酮引起的急性eGFR变化

2026-09-160
OAAI
Finerenone and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction

非奈利酮对射血分数轻度降低或保留的心力衰竭患者中表观治疗抵抗性高血压的影响

2026-08-170
OAAI
Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals

在640万个人中预防和评分2心血管风险方程的跨国验证

2026-05-050
OAAI
Lifetime benefits of finerenone on cardiorenal morbidity and mortality in chronic kidney disease and type 2 diabetes: a pooled analysis of FIDELIO-DKD and FIGARO-DKD trials

慢性肾脏病和2型糖尿病中非奈利酮对心肾患病率和死亡率的全生命周期获益:FIDELIO-DKD和FIGARO-DKD试验的合并分析

2026-04-070
PRE
Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes

根据慢性肾脏病和2型糖尿病基线心力衰竭风险,非奈利酮对心力衰竭结局的影响

2026-03-250
OAAI
Finerenone in Type 1 Diabetes and Chronic Kidney Disease

非奈利酮在1型糖尿病和慢性肾脏病中的应用

2026-03-0510
PRE
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure

Finerenone及根据基线肾功能的心力衰竭患者心血管结局

2025-12-050
PRE
Finerenone and eGFR Slope across Different Levels of Baseline Albuminuria and eGFR Insights from FINEARTS-HF

非奈利酮和eGFR斜率在不同基线白蛋白尿和eGFR水平下的差异:FINEARTS-HF研究启示

2025-11-010
PRE
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS-HF

血清钾与肾功能对非奈利酮在轻度射血分数降低或保留的心力衰竭中的相互作用:FINEARTS-HF研究的结果

2025-10-020
OAAI
Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations

比较CKD、T1D和T2D人群:基于FINE-ONE和FIDELITY人群的视角

2025-10-010
OAAI
Changing paradigms of studies in kidney diseases

肾脏疾病研究范式的转变

2025-09-290
OAAI
Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial

根据胰岛素抵抗在心力衰竭中的作用:FINEARTS-HF试验的见解

2025-09-080
OAAI
Effect of Finerenone on Morbidity and Mortality in CKD

非奈利酮对CKD患者发病率和死亡率的影响

2025-09-010
OA
Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome The FINE-HEART Pooled Analysis

Finerenone 可降低整个心-肾-代谢综合征谱中的新发心房颤动发生率 FINE-HEART 合并分析

2025-05-012
OAAI
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF

非奈利酮在心力衰竭伴轻度降低或保留射血分数患者中对分层复合终点的疗效分析:基于win统计学的FINEARTS-HF研究预设分析

2025-04-290
OA
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

非奈利酮、血糖状态以及射血分数轻度降低或保留的心力衰竭:一项FINEARTS-HF试验的预先指定分析

2025-04-100
OAAI
Finerenone Across the Spectrum of Kidney Risk in Heart Failure

在心力衰竭中不同肾脏风险下的非奈利酮

2025-04-020
PRE